WVP
CGTX icon

Worth Venture Partners’s Cognition Therapeutics CGTX Stock Holding History

Worth Venture Partners’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-508,719
Closed -$941K – 81
2023
Q4 		$941K Hold
508,719
– – 0.51% 63
2023
Q3 		$733K Hold
508,719
– – 0.43% 63
2023
Q2 		$931K Buy
508,719
+7,000
+1% +$14.8K 0.51% 54
2023
Q1 		$993K Hold
501,719
– – 0.48% 56
2022
Q4 		$1.05M Buy
501,719
+301,531
+151% +$609K 0.62% 50
2022
Q3 		$380K Sell
200,188
-27,982
-12% -$58.3K 0.23% 86
2022
Q2 		$459K Buy
228,170
+52,804
+30% +$136K 0.27% 79
2022
Q1 		$473K Buy
+175,366
New +$676K 0.22% 83

Other funds holding CGTX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
TIM
Timelo Investment Management Aurora, Ontario, Canada $349M AUM 28.06% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
HWM
Hohimer Wealth Management Seattle, Washington $1B AUM 33.02% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Worth Venture Partners's CGTX Position: Q1 2024 in Review

Worth Venture Partners sold out of Cognition Therapeutics (CGTX) in Q1 2024, closing a stake of 508,719 shares — an estimated $941K sold.

Worth Venture Partners first reported a position in CGTX in Q1 2022 and held it in 8 quarters. The position peaked at $1.05M in Q4 2022. 47 funds tracked by Wall St. Rank hold CGTX as of Q1 2024.

  • Worth Venture Partners reported no remaining Cognition Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Worth Venture Partners sold 508,719 Cognition Therapeutics shares in Q1 2024, an estimated $941K.
  • Worth Venture Partners first reported a position in Cognition Therapeutics in Q1 2022 and held it in 8 quarters.
  • Worth Venture Partners's Cognition Therapeutics position peaked at $1.05M in Q4 2022.
  • 47 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.